Last checked at 30 Apr 2012 12:17
This announcement replaces the one sent at 07.00 on RNS number 2980C on Monday 30th April. Correction to date of AGM to 30 June 2012.
BEXIMCO PHARMACEUTICALS LTD.
30th April, 2012
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Ltd. ("BPL" or "Company": AIM Symbol:BXP) today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 28th April, 2012 has decided the following:
1. | To recommend the approval of the Financial Statements for the year ended 31 December 2011 | : | The Audited Financial Statements for the year ended 31 December 2011 has been approved. The full accounts are expected to be released week commencing 7th May 2012 |
2. | Date & Time of 36th AGM of the Company for the year 2011 | : | 30 June, 2012 at 10.30 am Bangladesh Time |
3. | Venue of AGM | : | Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh |
4. | Proposed Dividend for the year ended 31 December 2011 | : | 21% Stock Dividend (i.e. 21 shares for every 100 shares held) |
5. | Record date | : | 21 May, 2012 |
6. | Net Asset Value as at 31 December 2011 | : | Taka 17,128,128,177 |
7. | Net Asset Value per Share as at 31 December, 2011 | : | Taka 68.03 |
8. | Earnings per share ( EPS) for the year ended 31 December 2011 | : | 4.76 |
9. | Net Operating Cash Flow per share for the year ended 31 December 2011 | : | 6.26 |
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 861 9151, ext.2080
Libertas Capital Corporate Finance
Thilo Hoffmann
Tel: +44 (0)20 7569 9650
FTI Consulting
Simon Conway / Susan Quigley/ Victoria Foster-Mitchell
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.